Search

Your search keyword '"Uzelac, Zeljko"' showing total 36 results
Start Over Author "Uzelac, Zeljko"
36 results on '"Uzelac, Zeljko"'

1. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study

Author

Günther, René, Wurster, Claudia Diana, Brakemeier, Svenja, Osmanovic, Alma, Schreiber-Katz, Olivia, Petri, Susanne, Uzelac, Zeljko, Hiebeler, Miriam, Thiele, Simone, Walter, Maggie C., Weiler, Markus, Kessler, Tobias, Freigang, Maren, Lapp, Hanna Sophie, Cordts, Isabell, Lingor, Paul, Deschauer, Marcus, Hahn, Andreas, Martakis, Kyriakos, Steinbach, Robert, Ilse, Benjamin, Rödiger, Annekathrin, Bellut, Julia, Nentwich, Julia, Zeller, Daniel, Muhandes, Mohamad Tareq, Baum, Tobias, Christoph Koch, Jan, Schrank, Bertold, Fischer, Sophie, Hermann, Andreas, Kamm, Christoph, Naegel, Steffen, Mensch, Alexander, Weber, Markus, Neuwirth, Christoph, Lehmann, Helmar C., Wunderlich, Gilbert, Stadler, Christian, Tomforde, Maike, George, Annette, Groß, Martin, Pechmann, Astrid, Kirschner, Janbernd, Türk, Matthias, Schimmel, Mareike, Bernert, Günther, Martin, Pascal, Rauscher, Christian, Meyer zu Hörste, Gerd, Baum, Petra, Löscher, Wolfgang, Flotats-Bastardas, Marina, Köhler, Cornelia, Probst-Schendzielorz, Kristina, Goldbach, Susanne, Schara-Schmidt, Ulrike, Müller-Felber, Wolfgang, Lochmüller, Hanns, von Velsen, Otgonzul, Kleinschnitz, Christoph, Ludolph, Albert C., and Hagenacker, Tim

Published
2024
Full Text
View/download PDF

2. Effects of tofersen treatment in patients with SOD1-ALS in a “real-world” setting – a 12-month multicenter cohort study from the German early access program

Author

Wiesenfarth, Maximilian, Dorst, Johannes, Brenner, David, Elmas, Zeynep, Parlak, Özlem, Uzelac, Zeljko, Kandler, Katharina, Mayer, Kristina, Weiland, Ulrike, Herrmann, Christine, Schuster, Joachim, Freischmidt, Axel, Müller, Kathrin, Siebert, Reiner, Bachhuber, Franziska, Simak, Tatiana, Günther, Kornelia, Fröhlich, Elke, Knehr, Antje, Regensburger, Martin, German, Alexander, Petri, Susanne, Grosskreutz, Julian, Klopstock, Thomas, Reilich, Peter, Schöberl, Florian, Hagenacker, Tim, Weyen, Ute, Günther, René, Vidovic, Maximilian, Jentsch, Martin, Haarmeier, Thomas, Weydt, Patrick, Valkadinov, Ivan, Hesebeck-Brinckmann, Jasper, Conrad, Julian, Weishaupt, Jochen Hans, Schumann, Peggy, Körtvélyessy, Peter, Meyer, Thomas, Ruf, Wolfgang Philipp, Witzel, Simon, Senel, Makbule, Tumani, Hayrettin, and Ludolph, Albert Christian

Published
2024
Full Text
View/download PDF

4. Pattern of pareses in 5q-spinal muscular atrophy.

Author

Uzelac, Zeljko, Schwäble, Beate, Dorst, Johannes, Rosenbohm, Angela, Wollinsky, Kurt, Wurster, Claudia D., Steinbreier, Janna S., and Ludolph, Albert C.

Subjects
MUSCULAR atrophy, SPINAL muscular atrophy, AMYOTROPHIC lateral sclerosis, PARALYSIS, MUSCLE weakness
Abstract

Background: This prospective study investigates the pattern of pareses in 5q-associated spinal muscular atrophy (SMA) to identify disease-specific characteristics and potential differences from amyotrophic lateral sclerosis (ALS) and spinobulbar muscular atrophy (SBMA). Detailed knowledge about pareses patterns in SMA facilitates differential diagnosis and supports therapeutic monitoring. Methods: Between January 2021, and June 2021, 66 SMA patients (59.1% male, aged 33.6 ± 15.2 years) were included in the study. Most patients had SMA type II (n = 28) or SMA type III (n = 28), seven patients had SMA type I, and three patients had SMA type IV. We analyzed the pattern of pareses using the UK Medical Research Council (MRC) scoring system. Results: In both, upper and lower limbs muscle weakness was less pronounced in distal (upper limbs: MRC median 3.0 (interquartile range 1.5–3.5); lower limbs: 1.5 (0.5–3.0)) compared to proximal muscle groups (upper limbs: 2.0 (1.5–2.6); p < 0.001; lower limbs: 0.5 (0.5–1.5); p < 0.001). Thenar muscles were stronger than other small hand muscles (3.0 (2.0–3.5) vs 3.0 (1.5–3.5); p = 0.004). Muscles had more strength in upper (2.3 (1.5–3.1)) compared to lower limbs (1.1 (0.5–2.3); p < 0.001) and in flexors compared to extensors. Conclusion: We identified a specific pattern of muscle paresis in SMA which is different from the pattern of paresis in ALS and SBMA. As a rule of thumb, the pattern of pareses is similar, but not identical to ALS in distal, but different in proximal muscle groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Staged treatment response in status epilepticus: Lessons from the SENSE registry.

Author

Beuchat, Isabelle, Novy, Jan, Rosenow, Felix, Kellinghaus, Christoph, Rüegg, Stephan, Tilz, Christian, Trinka, Eugen, Unterberger, Iris, Uzelac, Zeljko, Strzelczyk, Adam, and Rossetti, Andrea O.

Abstract

Objectives: Although in epilepsy patients the likelihood of becoming seizure‐free decreases substantially with each unsuccessful treatment, to our knowledge this has been poorly investigated in status epilepticus (SE). We aimed to evaluate the proportion of SE cessation and functional outcome after successive treatment steps. Methods: We conducted a post hoc analysis of a prospective, observational, multicenter cohort (Sustained Effort Network for treatment of Status Epilepticus [SENSE]), in which 1049 incident adult SE episodes were prospectively recorded at nine European centers. We analyzed 996 SE episodes without coma induction before the third treatment step. Rates of SE cessation, mortality (in ongoing SE or after SE control), and favorable functional outcome (assessed with modified Rankin scale) were evaluated after each step. Results: SE was treated successfully in 838 patients (84.1%), 147 (14.8%) had a fatal outcome (36% of them died while still in SE), and 11 patients were transferred to palliative care while still in SE. Patients were treated with a median of three treatment steps (range 1–13), with 540 (54.2%) receiving more than two steps (refractory SE [RSE]) and 95 (9.5%) more than five steps. SE was controlled after the first two steps in 45%, with an additional 21% treated after the third, and 14% after the fourth step. Likelihood of SE cessation (p < 0.001), survival (p = 0.003), and reaching good functional outcome (p < 0.001) decreased significantly between the first two treatment lines and the third, especially in patients not experiencing generalized convulsive SE, but remained relatively stable afterwards. Significance: The significant worsening of SE prognosis after the second step clinically supports the concept of RSE. However, and differing from findings in human epilepsy, RSE remains treatable in about one third of patients, even after several failed treatment steps. Clinical judgment remains essential to determine the aggressiveness and duration of SE treatment, and to avoid premature treatment cessation in patients with SE. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers—A Prospective, Cross-Sectional, Multi-Center Analysis

Author

Wohnrade, Camilla, primary, Velling, Ann-Kathrin, additional, Mix, Lucas, additional, Wurster, Claudia D., additional, Cordts, Isabell, additional, Stolte, Benjamin, additional, Zeller, Daniel, additional, Uzelac, Zeljko, additional, Platen, Sophia, additional, Hagenacker, Tim, additional, Deschauer, Marcus, additional, Lingor, Paul, additional, Ludolph, Albert C., additional, Lulé, Dorothée, additional, Petri, Susanne, additional, Osmanovic, Alma, additional, and Schreiber-Katz, Olivia, additional

Published
2023
Full Text
View/download PDF

12. Prevalence of Anti-Adeno-Associated Virus Serotype 9 Antibodies in Adult Patients with Spinal Muscular Atrophy

Author

Stolte, Benjamin, primary, Schreiber-Katz, Olivia, additional, Günther, René, additional, Wurster, Claudia Diana, additional, Petri, Susanne, additional, Osmanovic, Alma, additional, Freigang, Maren, additional, Uzelac, Zeljko, additional, Leo, Markus, additional, von Velsen, Otgonzul, additional, Bayer, Wibke, additional, Dittmer, Ulf, additional, Kleinschnitz, Christoph, additional, and Hagenacker, Tim, additional

Published
2022
Full Text
View/download PDF

14. Validity and reliability of the German multidimensional fatigue inventory in spinal muscular atrophy

Author

Binz, Camilla, primary, Osmanovic, Alma, additional, Thomas, Nele H., additional, Stolte, Benjamin, additional, Freigang, Maren, additional, Cordts, Isabell, additional, Griep, Ramona, additional, Uzelac, Zeljko, additional, Wurster, Claudia D., additional, Kamm, Christoph, additional, Siegler, Hannah A., additional, Wieselmann, Gary, additional, Hermann, Andreas, additional, Lingor, Paul, additional, Deschauer, Marcus, additional, Ludolph, Albert C., additional, Meyer, Thomas, additional, Günther, René, additional, Hagenacker, Tim, additional, Petri, Susanne, additional, and Schreiber‐Katz, Olivia, additional

Published
2022
Full Text
View/download PDF

16. Quality of Life in SMA Patients Under Treatment With Nusinersen

Author

Mix, Lucas, Winter, Benedikt, Wurster, Claudia, Platen, Sophia, Witzel, Simon, Uzelac, Zeljko, Graf, Heiko, Ludolph, Albert C, and Lulé, Dorothée

Subjects
antisense oligonucleotide, Quality of life, Muscular atrophy, Spinal, Well-being, Brief Research Report, Oligonucleotides, Antisense, Patient reported outcome, Neurology, Spinale Muskelatrophie, Oligonucleotide, nusinersen (Spinraza), ddc:610, Rusinersen (Spinraza), DDC 610 / Medicine & health, Depressiveness, spinal muscular atrophy, Lebensqualität
Abstract

Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease progression with a potentially major impact on patients' well-being. Objective: This study evaluates quality of life (QoL) in pediatric and adult patients over the course of therapy with nusinersen. Methods: Twenty-six SMA patients treated with nusinersen were evaluated regarding global QoL (gQoL), health-related QoL (HRQoL) and depressiveness. Assessments were conducted three times over the first 6 months of treatment. Applied were different questionnaires: the Anamnestic Comparative Self-Assessment (ACSA) for gQoL, the Short Form-36 Health Survey (SF-36) for HRQoL in adult patients and the ALS Depression Inventory 12 Items (ADI-12) for depressiveness. The sample was matched with 22 healthy controls. Results: Despite severe physical restrictions, patients reported high levels of QoL and low levels of depressiveness at study entry. Early disease onset and low levels of physical functioning were associated with better gQoL and lower levels of depressiveness. A significant decrease of gQoL in patients was evident over the course of the study. Still, adult patients reported a significant increase in perceived health. Conclusions: Our study provides first insight that SMA patients experience a gQoL superior to healthy controls at start of therapy. This might indicate patients' high hopes and expectations toward treatment. gQoL returns to a level similar to that of healthy controls over the course of therapy., publishedVersion

Published
2021

17. Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA)

Author

Mix, Lucas John, Schreiber���Katz, Olivia, Wurster, Claudia D., Uzelac, Zeljko, Platen, Sophia, Gipperich, Christina, Ranxha, Gresa, Wieselmann, Gary, Osmanovic, Alma, Ludolph, Albert C., Petri, Susanne, and Lul��, Doroth��e

Subjects
Adult, Hammersmith functional motor scale expanded (HFMSE), Research, lcsh:R, lcsh:Medicine, Cognitive adaptation, Spinal Muscular Atrophies of Childhood, Spinal muscular atrophy, Social cognition, Muscular Atrophy, Spinal, Executive Function, Cognition, Cross-Sectional Studies, Spinale Muskelatrophie, Humans, Edinburgh cognitive and behavioural ALS screen (ECAS), ddc:610, SMA, Reading the mind in the eyes test, Child, DDC 610 / Medicine & health, Kognition
Abstract

Background: Spinal muscular atrophy (SMA) issues from mutations in the survival of motor neuron (SMN) 1 gene. Loss or reduction of the SMN protein results in progressive muscle weakness. Whether this protein deficiency also affects cortical function remains unclear. While no data on adult patients exists so far, prior studies in children with SMA indicate cognitive abilities equal or even superior to healthy controls. This may suggest a possible compensatory���neuropsychological and interactional���process. The goal of this study was to assess the cognitive profile of adult patients with SMA, with a special focus on social cognition as a potential candidate for enhanced cognitive function through compensatory processes. Methods: In a cross-sectional design, N = 31 adult SMA patients (types II and III) were assessed for language, verbal fluency, memory, visuospatial abilities and executive function with the Edinburgh Cognitive and Behavioural ALS Screen and for social cognition with the Reading the Mind in the Eyes Test. Physical function was evaluated using the Hammersmith Functional Motor Scale Expanded. N = 19 neurologically healthy controls were matched with patients for age, sex and years of education. Results: In none of the abovementioned cognitive domains significant differences between SMA patients and controls were found. Among patients, no differences between type II SMA and type III SMA were detected for any domain. However, a trend towards better social cognition in patients with type II SMA, compared to those with type III SMA was observed. Furthermore, a significant inverse correlation of physical function and executive function was detected: lower motor function was associated with a better executive function. Conclusions: This study shows cognitive abilities in adult SMA in the normal range for all assessed domains. Thus, reduction of SMN protein has no obvious negative impact on cognitive function. Executive functions are identified as the only cognitive domain correlated with disease severity. Therefore, executive functions may play a role in the adaptation to physical restrictions in SMA, making them a promising target for future research., publishedVersion

Published
2021

18. Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism

Author

Kivell, Bronwyn, Uzelac, Zeljko, Sundaramurthy, Santhanalakshmi, Rajamanickam, Jeyaganesh, Ewald, Amy, Chefer, Vladimir, Jaligam, Vanaja, Bolan, Elizabeth, Simonson, Bridget, Annamalai, Balasubramaniam, Mannangatti, Padmanabhan, Prisinzano, Thomas E., Gomes, Ivone, Devi, Lakshmi A., Jayanthi, Lankupalle D., Sitte, Harald H., Ramamoorthy, Sammanda, and Shippenberg, Toni S.

Published
2014
Full Text
View/download PDF

19. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen

Author

Meyer, Thomas, primary, Maier, André, additional, Uzelac, Zeljko, additional, Hagenacker, Tim, additional, Günther, René, additional, Schreiber‐Katz, Olivia, additional, Weiler, Markus, additional, Steinbach, Robert, additional, Weyen, Ute, additional, Koch, Jan Christoph, additional, Kettemann, Dagmar, additional, Norden, Jenny, additional, Dorst, Johannes, additional, Wurster, Claudia, additional, Ludolph, Albert C., additional, Stolte, Benjamin, additional, Freigang, Maren, additional, Osmanovic, Alma, additional, Petri, Susanne, additional, Grosskreutz, Julian, additional, Rödiger, Annekathrin, additional, Griep, Ramona, additional, Gaudlitz, Marcel, additional, Walter, Bertram, additional, Münch, Christoph, additional, and Spittel, Susanne, additional

Published
2021
Full Text
View/download PDF

20. Refractory Status Epilepticus

Author

Beuchat, Isabelle, Rosenow, Felix, Kellinghaus, Christoph, Trinka, Eugen, Unterberger, Iris, Rüegg, Stephan, Sutter, Raoul, Tilz, Christian, Uzelac, Zeljko, Rossetti, Andrea O., and Strzelczyk, Adam

Published
2022
Full Text
View/download PDF

22. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.44

Author

Wurster, Claudia D, Steinacker, Petra, Schreiber-Katz, Olivia, Al Shweiki, Rami, Ludolph, Albert C, Petri, Susanne, Hermann, Andreas, Otto, Markus, MND-Net, Günther, René, Koch, Jan C, Lingor, Paul, Uzelac, Zeljko, Witzel, Simon, Wollinsky, Kurt, Winter, Benedikt, and Osmanovic, Alma

Subjects
Adult, Male, pharmacology [Oligonucleotides], drug therapy [Spinal Muscular Atrophies of Childhood], Adolescent, blood [Spinal Muscular Atrophies of Childhood], drug therapy [Muscular Atrophy, Spinal], physiopathology [Spinal Muscular Atrophies of Childhood], blood [Neurofilament Proteins], Middle Aged, physiopathology [Muscular Atrophy, Spinal], Severity of Illness Index, drug effects [Neurofilament Proteins], Young Adult, blood [Muscular Atrophy, Spinal], Outcome Assessment, Health Care, Humans, Female, ddc:610, Child, Follow-Up Studies
Abstract

To determine the diagnostic and monitoring value of serum neurofilament light chain (NfL) in spinal muscular atrophy (SMA).We measured serum NfL in 46 SMA patients at baseline and over 14 months of treatment with the antisense-oligonucleotide (ASO) nusinersen using the ultrasensitive single molecule array (Simoa) technology. Serum NfL levels of SMA patients were compared to controls and related to cerebrospinal fluid (CSF) NfL, blood-CSF barrier function quantified by the albumin blood/CSF ratio (Qalb) and motor scores (Hammersmith Functional Motor Scale Expanded, HFMSE; Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, ALSFRS-R).Serum NfL levels of SMA patients were in the range of controls (p = 0.316) and did not correlate with CSF NfL (ρ = 0.302, p = 0.142) or Qalb (ρ = - 0.160, p = 0.293). During therapy, serum NfL levels were relatively stable with notable concentration changes in single SMA patients, however, within the control range. Higher NfL levels were associated with worse motor performance in SMA (baseline: HFMSE ρ = - 0.330, p = 0.025, ALSFRS-R ρ = - 0.403, p = 0.005; after 10 months: HFMSE ρ = - 0.525, p = 0.008, ALSFRS-R ρ = - 0.537, p = 0.007), but changes in motor scores did not correlate with changes in serum NfL.Diagnostic and monitoring performance of serum NfL measurement seems to differ between SMA subtypes. Unlike to SMA type 1, in adolescent and adult SMA type 2 and 3 patients, neurodegeneration is not reflected by increased NfL levels and short-term therapeutic effects cannot be observed. Long-term follow-up has to be performed to see if even low levels of NfL might be good prognostic markers.

Published
2020

24. Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen

Author

Wurster, Claudia D., primary, Koch, Jan C., additional, Cordts, Isabell, additional, Dreyhaupt, Jens, additional, Otto, Markus, additional, Uzelac, Zeljko, additional, Witzel, Simon, additional, Winter, Benedikt, additional, Kocak, Tugrul, additional, Schocke, Michael, additional, Weydt, Patrick, additional, Wollinsky, Kurt, additional, Ludolph, Albert C., additional, Deschauer, Marcus, additional, Lingor, Paul, additional, Tumani, Hayrettin, additional, Hermann, Andreas, additional, and Günther, René, additional

Published
2019
Full Text
View/download PDF

25. Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE)

Author

Kellinghaus, Christoph, primary, Rossetti, Andrea O., additional, Trinka, Eugen, additional, Lang, Nicolas, additional, May, Theodor W., additional, Unterberger, Iris, additional, Rüegg, Stephan, additional, Sutter, Raoul, additional, Strzelczyk, Adam, additional, Tilz, Christian, additional, Uzelac, Zeljko, additional, and Rosenow, Felix, additional

Published
2019
Full Text
View/download PDF

26. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment

Author

Wurster, Claudia D., primary, Günther, René, additional, Steinacker, Petra, additional, Dreyhaupt, Jens, additional, Wollinsky, Kurt, additional, Uzelac, Zeljko, additional, Witzel, Simon, additional, Kocak, Tugrul, additional, Winter, Benedikt, additional, Koch, Jan C., additional, Lingor, Paul, additional, Petri, Susanne, additional, Ludolph, Albert C., additional, Hermann, Andreas, additional, and Otto, Markus, additional

Published
2019
Full Text
View/download PDF

28. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Author

Wurster, Claudia D., Steinacker, Petra, Günther, René, Koch, Jan C., Lingor, Paul, Uzelac, Zeljko, Witzel, Simon, Wollinsky, Kurt, Winter, Benedikt, Osmanovic, Alma, Schreiber-Katz, Olivia, Al Shweiki, Rami, Ludolph, Albert C., Petri, Susanne, Hermann, Andreas, and Otto, Markus

Subjects
SPINAL muscular atrophy, AMYOTROPHIC lateral sclerosis, CYTOPLASMIC filaments, CEREBROSPINAL fluid, SERUM
Abstract

Objective: To determine the diagnostic and monitoring value of serum neurofilament light chain (NfL) in spinal muscular atrophy (SMA). Methods: We measured serum NfL in 46 SMA patients at baseline and over 14 months of treatment with the antisense-oligonucleotide (ASO) nusinersen using the ultrasensitive single molecule array (Simoa) technology. Serum NfL levels of SMA patients were compared to controls and related to cerebrospinal fluid (CSF) NfL, blood-CSF barrier function quantified by the albumin blood/CSF ratio (Qalb) and motor scores (Hammersmith Functional Motor Scale Expanded, HFMSE; Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, ALSFRS-R). Results: Serum NfL levels of SMA patients were in the range of controls (p = 0.316) and did not correlate with CSF NfL (ρ = 0.302, p = 0.142) or Qalb (ρ = − 0.160, p = 0.293). During therapy, serum NfL levels were relatively stable with notable concentration changes in single SMA patients, however, within the control range. Higher NfL levels were associated with worse motor performance in SMA (baseline: HFMSE ρ = − 0.330, p = 0.025, ALSFRS-R ρ = − 0.403, p = 0.005; after 10 months: HFMSE ρ = − 0.525, p = 0.008, ALSFRS-R ρ = − 0.537, p = 0.007), but changes in motor scores did not correlate with changes in serum NfL. Conclusion: Diagnostic and monitoring performance of serum NfL measurement seems to differ between SMA subtypes. Unlike to SMA type 1, in adolescent and adult SMA type 2 and 3 patients, neurodegeneration is not reflected by increased NfL levels and short-term therapeutic effects cannot be observed. Long-term follow-up has to be performed to see if even low levels of NfL might be good prognostic markers. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

29. SENSE registry for status epilepticus

Author

Kellinghaus, Christoph, primary, Rossetti, Andrea O., additional, Trinka, Eugen, additional, Lang, Nicolas, additional, Unterberger, Iris, additional, Rüegg, Stephan, additional, Tilz, Christian, additional, Uzelac, Zeljko, additional, and Rosenow, Felix, additional

Published
2018
Full Text
View/download PDF

32. Platelet Serotonin Transporter Function Predicts Default-Mode Network Activity

Author

Scharinger, Christian, primary, Rabl, Ulrich, additional, Kasess, Christian H., additional, Meyer, Bernhard M., additional, Hofmaier, Tina, additional, Diers, Kersten, additional, Bartova, Lucie, additional, Pail, Gerald, additional, Huf, Wolfgang, additional, Uzelac, Zeljko, additional, Hartinger, Beate, additional, Kalcher, Klaudius, additional, Perkmann, Thomas, additional, Haslacher, Helmuth, additional, Meyer-Lindenberg, Andreas, additional, Kasper, Siegfried, additional, Freissmuth, Michael, additional, Windischberger, Christian, additional, Willeit, Matthäus, additional, Lanzenberger, Rupert, additional, Esterbauer, Harald, additional, Brocke, Burkhard, additional, Moser, Ewald, additional, Sitte, Harald H., additional, and Pezawas, Lukas, additional

Published
2014
Full Text
View/download PDF

33. Unifying Concept of Serotonin Transporter-associated Currents

Author

Schicker, Klaus, primary, Uzelac, Zeljko, additional, Gesmonde, Joan, additional, Bulling, Simon, additional, Stockner, Thomas, additional, Freissmuth, Michael, additional, Boehm, Stefan, additional, Rudnick, Gary, additional, Sitte, Harald H., additional, and Sandtner, Walter, additional

Published
2012
Full Text
View/download PDF

34. The Large Extracellular Loop of Organic Cation Transporter 1 Influences Substrate Affinity and Is Pivotal for Oligomerization

Author

Keller, Thorsten, primary, Egenberger, Brigitte, additional, Gorboulev, Valentin, additional, Bernhard, Frank, additional, Uzelac, Zeljko, additional, Gorbunov, Dmitry, additional, Wirth, Christophe, additional, Koppatz, Stefan, additional, Dötsch, Volker, additional, Hunte, Carola, additional, Sitte, Harald H., additional, and Koepsell, Hermann, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results